Format

Send to

Choose Destination
Ann Intern Med. 2018 Nov 6;169(9):ITC65-ITC80. doi: 10.7326/AITC201811060.

Nonalcoholic Fatty Liver Disease.

Author information

1
From the Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota. (X.J.W., H.M.).

Abstract

Nonalcoholic fatty liver disease (NAFLD) is the leading cause of chronic liver disease. Most cases are diagnosed incidentally in the primary care or hospital setting on the basis of elevated liver enzyme levels or hepatic steatosis on imaging. NAFLD encompasses a wide spectrum: The vast majority of patients have nonprogressive nonalcoholic fatty liver, and a few of those develop progressive liver injury, inflammation, and fibrosis, a condition termed nonalcoholic steatohepatitis. Cardiovascular disease is the leading cause of death in patients with nonalcoholic fatty liver disease. Persons with nonalcoholic steatohepatitis have increased liver-related mortality. In the absence of regulatory agency-approved drugs, lifestyle modification and weight loss remain the cornerstones of NAFLD therapy.

PMID:
30398639
DOI:
10.7326/AITC201811060

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center